Summary
3,4-DMMC was first detected in Europe in 2010 and marketed under street names "Ocean" and "M2" as a mephedrone replacement. Potency is noticeably lower than mephedrone; users describe effects as "blunted" or "foggy." Nasal administration produces pronounced chemical burn and rhinorrhea. Pharmacodynamic data show similar affinity at norepinephrine and serotonin transporters but weaker dopamine transporter activity compared to mephedrone, resulting in mild empathogenic effects and potentially higher cardiovascular strain. Physical risks mirror other stimulants: tachycardia, vasoconstriction, hypertension, bruxism, dehydration, and potential hyperthermia in hot environments. Harm-reduction: weigh doses on a 0.001 g scale, allow at least 2 weeks between sessions, maintain hydration/electrolytes, and avoid stacking with other stimulants or serotonergic agents.
Dose Information
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Oral | 15-30 min | 30-60 min | 1-2 hrs | 60 min | 2-8 hrs |
| Insufflated | 5-10 min | 15-30 min | 30-60 min | 60 min | 2-8 hrs |
Tolerance
Effects
- Stimulation
- Teeth grinding
- Vasoconstriction
- Increased heart rate
- Increased blood pressure
- Pupil dilation
- Increased perspiration
- Insomnia
- Nasal irritation
- Decreased appetite
- Cognitive euphoria
- Sociability enhancement
- Empathy
- Euphoria
- Wakefulness
- Compulsive redosing
- Cognitive fog
- Anxiety
- Depression
- Thought acceleration
- Music enhancement
- Tactile enhancement
- Increased libido
- Increased music appreciation
- Tracers
- Color enhancement
- Appetite suppression
- Dehydration
- Light sensitivity
- Disinhibition